03:20 PM EDT, 05/17/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target price by $2 to $15, applying an EV/revenue multiple of 1.1x to our 2024 EPS estimate, a discount to most health care technology peers, reflecting our low growth outlook. We move our 2024 loss per share estimate to -$1.01 from -$1.02 and move our 2025 loss per share estimate to -$0.59 from -$0.66. TDOC reported a Q1 operating loss of -$0.43 vs. a loss of -$0.34, $0.01 better than the consensus. Q1 revenue grew 3%, supported by 7.8% growth in Integrated Care revenue, which benefited from high-single-digit growth in its Chronic Care book of business, as well as strong visit revenues, driven by increased infectious disease activity and an 8% increase in memberships, partially offset by a 4% decline in the BetterHelp segment, driven by an 11% decrease in paying users. Total Chronic Care program enrollment was 1.12 million, representing 9% growth, while U.S. Integrated Care members grew 6.9 million, or 8%.